Cargando…

Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data

BACKGROUND: Before the introduction of the immunomodulatory therapies for multiple sclerosis (MS), treatment options for MS consisted of symptomatic management (physical therapy and pharmacological treatment for symptom management). Symptomatic management for MS has been supplemented in the past dec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bell, Christopher, Graham, Jonathan, Earnshaw, Stephanie, Oleen-Burkey, MerriKay, Castelli-Haley, Jane, Johnson, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2007
Materias:	Formulary Management
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438176/ https://www.ncbi.nlm.nih.gov/pubmed/17407391 http://dx.doi.org/10.18553/jmcp.2007.13.3.245

Ejemplares similares

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey
por: Hadjimichael, Olympia, et al.
Publicado: (2008)

Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
por: Oleen-Burkey, MerriKay, et al.
Publicado: (2014)

Pregnancy Complications Associated With Bacterial Vaginosis and Their Estimated Costs
por: Oleen-Burkey, MerriKay A., et al.
Publicado: (1995)

Pharmacy Benefit Forecast for a New Interferon Beta-1a for the Treatment of Multiple Sclerosis: Development of a First-Line Decision Tool for Pharmacy-Budget Planning Using Administrative Claims Data
por: Meryer, Christina
Publicado: (2003)

Health Plan Budget Impact Analysis for Pimecrolimus
por: Chang, Jane, et al.
Publicado: (2005)

Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization
por: Billups, Sarah J., et al.
Publicado: (2005)

Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy With Pimecrolimus or Tacrolimus
por: Delea, Thomas E., et al.
Publicado: (2007)

Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes
por: Coyle, Patricia K, et al.
Publicado: (2014)

A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults
por: Payakachat, Nalin, et al.
Publicado: (2006)

Cost-Effectiveness Analysis and the Formulary Decision-Making Process
por: Wang, Zhixiao, et al.
Publicado: (2004)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis
por: Fisher, Vicki S.
Publicado: (2005)

Multicenter Drug Use Evaluation of Tamsulosin and Availability of Guidance Criteria for Nonformulary Use in the Veterans Affairs Health System
por: Burk, Muriel, et al.
Publicado: (2004)

Similar Medication Compliance and Control of Dyslipidemia WithSimvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic
por: Valdez, Connie A., et al.
Publicado: (2005)

Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)

Proton-Pump Inhibitor Utilization Associated With the Change to Nonpreferred Formulary Status for Esomeprazole in the TRICARE Formulary
por: Linton, Andrea, et al.
Publicado: (2009)

Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat
por: Mullins, C. Daniel
Publicado: (2005)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan
por: Ramsey, Scott D., et al.
Publicado: (2006)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Formulary Management of 2 New Agents: Lorcaserin and Phentermine/Topiramate for Weight Loss
por: Kelly, Elizabeth M., et al.
Publicado: (2013)

Comparison of Risedronate to Alendronate and Calcitonin for Early Reduction of Nonvertebral Fracture Risk: Results From a Managed Care Administrative Claims Database
por: Watts, Nelson B., et al.
Publicado: (2004)

A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System
por: Belperio, Pamela S., et al.
Publicado: (2014)

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
por: Morrison, Vicki A., et al.
Publicado: (2007)

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
por: Campbell, Helen Eloise
Publicado: (2005)

Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches
por: Gershovich, Olga E., et al.
Publicado: (2006)

Drug and Medical Cost Effects of a Drug Formulary Change With Therapeutic Interchange for Statin Drugs in a Multistate Managed Medicaid Organization
por: Meissner, Brian, et al.
Publicado: (2006)

Managed Care Perspective on Three New Agents for Type 2 Diabetes
por: VanDeKoppel, Shawna, et al.
Publicado: (2008)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

Product-Line Extensions and Pricing Strategies of Brand-Name Drugs Facing Patent Expiration
por: Hong, Song Hee, et al.
Publicado: (2005)

AMCP Format Dossier Requests: Manufacturer Response and Formulary Implications for One Large Health Plan
por: Spooner, Joshua J., et al.
Publicado: (2007)

Industry's Perception of Presenting Pharmacoeconomic Models to Managed Care Organizations
por: Olson, Bridget M., et al.
Publicado: (2003)

Determinants of the Cost-Effectiveness of Statins
por: Morrison, Alan, et al.
Publicado: (2003)

Do Decision-Analytic Models Identify Cost-Effective Treatments? A Retrospective Look at Helicobacter Pylori Eradication
por: Fairman, Kathleen A., et al.
Publicado: (2003)

Alternate Financial Incentives in Multi-tiered Formulary Systems to Improve Accountability for Outcomes
por: Chung, Richard S., et al.
Publicado: (2003)

Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES
por: Ofman, Joshua J., et al.
Publicado: (2003)

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

A Comparison of the Cost-Effectiveness of Almotriptan and Sumatriptan in the Treatment of Acute Migraine Using a Composite Efficacy/Tolerability End Point
por: Williams, Paul, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_fa1vf233t16uaj9852adka2ptr